Nemtabrutinib, bortezomib, and rituximab for Waldenstrom's macroglobulinemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) for people with Waldenstrom's macroglobulinemia (a rare blood cancer) who have not yet had treatment. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Waldenstrom's macroglobulinemia and have never been treated for it.
- Your disease must be causing symptoms that need treatment, like fatigue, bleeding, or nerve problems.
- You must have a blood level of a protein called IgM above 0.5 g/dL.
- You need to be at least 19 years old.
- If you are able to have children, you must agree to use effective birth control during and for a time after treatment.
- You must be able to swallow and keep down oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
This trial tests a combination of two drugs—mosunetuzumab and pirtobrutinib—in patients whose Waldenstrom macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The study aims to see if this combination can shrink tumors and help patients feel better.
This trial tests a combination of two targeted drugs, zanubrutinib and BGB-11417, for people with Waldenström Macroglobulinemia who have already had at least one prior treatment. The goal is to see if this two-drug approach works better than standard options.
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.